Analysts Estimate Organon (OGN) to Report a Decline in Earnings: What to Look Out forZacks Investment Research • 04/24/25
Organon To Report First Quarter 2025 Results and Host Conference Call on May 1, 2025Business Wire • 04/15/25
Strength Seen in Organon (OGN): Can Its 8.5% Jump Turn into More Strength?Zacks Investment Research • 04/10/25
Organon Acquires TOFIDENCE™ (tocilizumab-bavi), a Commercialized Biosimilar to ACTEMRA® (tocilizumab) Injection, for Intravenous Infusion in the U.S.Business Wire • 04/01/25
European Medicines Agency (EMA) Validates Henlius and Organon Filing for Perjeta® (pertuzumab) Biosimilar Candidate HLX11Business Wire • 03/28/25
Organon (OGN) Advances While Market Declines: Some Information for InvestorsZacks Investment Research • 03/18/25
New Analysis of Organon's VTAMA® (tapinarof) cream, 1% Phase 3 Data Shows Atopic Dermatitis Disease Activity Remained Low After Treatment-Free Interval in Adults and Children 2 Years of Age and OlderBusiness Wire • 03/08/25
Organon Reports Results for the Fourth Quarter and Full Year Ended December 31, 2024Business Wire • 02/13/25
Organon To Report Fourth Quarter and Full Year 2024 Results and Host Conference Call on February 13, 2025Business Wire • 01/23/25